Skip to main
ORGO

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings is a leading player in the regenerative medicine market, with a diverse portfolio of products that address a range of chronic wounds and musculoskeletal injuries. While recent reimbursement changes have been a headwind for the company, we believe Organogenesis will emerge as a market leader as smaller players exit the space due to unfavorable economics. Additionally, the company's promising new product, ReNu, could provide significant upside once it receives FDA approval and reimbursement is settled. Overall, we expect Organogenesis to continue its strong growth trajectory in the long term.

Bears say

Organogenesis Holdings is facing significant challenges in the near future, with a decline in revenue and profitability expected in 2026 due to confusion in the provider level leading to decreased sales and limited visibility in their business. The company operates in a single segment, with a diverse portfolio of regenerative medicine products, but faces competition in the wound care sector and uncertainty surrounding their new product ReNu. Additionally, changes in reimbursement policies and regulations from CMS could have a significant impact on the company's financial performance. However, the company's strong product offering and potential for growth in the future, particularly with the launch of ReNu, could mitigate some of these challenges.

Organogenesis Holdings (ORGO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 2 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Aug 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.